Powered by
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has sold 32,142,858 additional shares of its common stock to the public for $225 million, before deducting underwriting discounts, commissions, and other offering expenses. …
CANTON TWP.—MMS Holdings, the contract research organization for the pharmaceutical industry, announced the hiring of Kevin Chartier as principal advisor of biostatistics and submissions planning.Chartier will work with the biostatistics …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), developers of a new class of cholesterol-lowering drugs, announced a 40 percent work force reduction and said it would focus its marketing efforts more …
ANN ARBOR—BlueWillow Biologics Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine …
CANTON TWP.—Officials at MMS Holdings Inc., a contract research organization for the pharmaceutical industry, announced a pro-bono support program to advance research for ultra-rare diseases. Within this program, MMS will …
ANN ARBOR—The pharmaceutical firm Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a rise in sales of its novel cholesterol-reducing drugs in the second quarter ended June 30 but still posted a …
CANTON TWP.—Officials at MMS Holdings, the Canton Township-based contract pharmaceutical research firm, announced that the company’s MMS Academy has launched new courses in inspection readiness and clinical programming for clinical …
GRAND RAPIDS—Officials at Tetra Therapeutics, a pharma startup developing drugs to treat brain disorders associated with cognitive and memory deficits, announced that CEO Mark Gurney had retired effective June 30. …
ANN ARBOR—Officials at the Ann Arbor cholesterol drug developer Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as chief medical officer, effective immediately. …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of Sheldon Koenig as president, CEO, and board member, effective immediately. He succeeds Tim Mayleben, whom company officials said “decided to …